WILMINGTON, Del.- AstraZeneca announced Monday that it acquired a Canadian biologics manufacturing facility from DSM Biologics Inc.
The 66,000 square foot facility will be used to manufacture antibody drug candidates for clinical trials for the AstraZeneca group.
“This is a further step in our global plan to accelerate the delivery of promising pre-clinical biopharmaceutical candidate drugs into our development portfolio,” said Dr. John Patterson, AstraZeneca’s Executive Director, Development. “It extends the set of supply capabilities we have assembled through MedImmune and Cambridge Antibody Technology (CAT) and takes advantage of the biotechnology skills in Quebec.”
The company will start to re-commission the facility and expects full scale production to begin in 2009.